

PROCARE HEALTH IBERIA AWARD FOR INNOVATION IN MEDICAL SOLUTIONS FOR WOMEN

Natural-based wellness

The first non-invasive treatment for lesions and recovery from Human Papillomavirus infection has been developed from botanical ingredients and without hormonal loading.

Elena Magariños-Madrid

Procare Health, a company focused on women's health and well-being, has developed a wide range of products designed for pathologies that mainly affect women, offering solutions in fields such as gynecology, osteoarthritis and osteoporosis. "It is very important that our products respond to unmet medical needs, but also demonstrate that they are a real solution for women in all stages of their lives," says Yann Gaslain, founder and CEO. Therefore, all Procare Health products have a strong clinical research plan behind with studies and trials, both own and independent that verify their effectiveness. "In addition, our commitment is to develop products that minimize adverse effects and are suitable for all women," he adds. For this reason, all are designed based on natural ingredients and are one hundred percent non-hormonal. "Innovation is a fundamental pillar of our philosophy, being the Spanish company with the



Yann Gaslain, founder and CEO of Procare Health Iberia, with the president of the Generalitat and the delegate of LA RAZÓN

STUDIES AT A GLOBAL LEVEL

As part of its commitment to innovation, since 2018 it has been leading a line of research together with Harvard Medical School, the University of California Los Angeles (UCLA) and, recently, with McMaster's in Canada. The objective of this project is to emulate the process of HPV infection. For that purpose, the first human cervix on a chip has been developed. This chip facilitates the study of the transformation zone of the uterine neck, in order to discover new therapies.

greatest investment in R&D in women's health", continues the CEO. This company has focused on providing solutions for unmet medical needs in every stage of women's lives. "In this sense, for example, we have developed Papilocare, the first and only treatment approved in Europe to treat and prevent low-grade cervical lesions caused by the human papilloma virus (HPV)," he explains. Previously, HPV-positive women with and without cervical lesions did not have access to an effective, non-invasive treatment. "Thanks to Papilocare, a window is opened to act directly and help the body eliminate the virus and normalize the lesions," Gaslain asserts. Procare Health is also a growing company, with headquarters in Spain and

subsidiaries in France, Portugal and the United Kingdom. "On the other hand, we have agreements for the commercialization of three of our products, Papilocare, Palomacare and Libicare, with different international distributors, both inside and outside Europe", he points out. The first one figures as the product with more international projection, since it is being commercialized in 22 countries and soon it will be launched in Colombia, Mexico, Lebanon, Vietnam and Russia. "We are preparing our landing in the United States, so continuing this internationalization and extending it to the rest of our products is, without a doubt, one of our main challenges for the coming years," Gaslain asserts. But, above all, he states that the most essential thing for the company is to maintain the

They have designed a natural product for sexual desire in front of the decrease of the libido due to the variations of the hormonal levels

confidence that doctors and patients have already placed in it by providing new data and scientific evidence of the reliability of their products.

HIGH QUALITY LEVEL

"We strive to ensure that all our products meet the highest quality requirements and, for this reason, all of our production and research is carried out in Spain under exhaustive safety and efficiency controls," he highlights. In this sense, the products developed by the company are supported by important research plans, with the sole purpose of demonstrating their effectiveness. "We have recently obtained the final results of the "Paloma" clinical trial, which it is demonstrated the efficacy of Papilocare in normalizing cervical lesions produced by the HPV virus and in viral

clearance". In addition, they have developed a natural product for the sexual desire considering the descent of the libido due to the different variations from the hormonal levels in women, whose prevalence is estimated that it can oscillate between the 25 and 63% in the feminine population. "It usually affects women with hormonal disorders or perimenopausal women due to other factors, such as postpartum, or the use of hormonal contraceptives, for example," he explains. "In spite of being a normal condition, it diminishes considerably the quality of life of these women, being able to affect even their relationship", points out. For that reason, they have elaborated Libicare, a food supplement in tablets based on botanical extracts, that "produce positive effects in the improvement of the sexual function of women with low desire", says.